Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity
of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of
Terameprocol(EM-1421)given as intravenous infusion three times a week in patients with
leukemia.